P/E ratio for Biolase (BIOL)
P/E ratio as of September 2023 (TTM): -1.07
According to Biolase 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.07317. At the end of 2021 the company had a P/E ratio of -0.1360.
P/E ratio history for Biolase from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -0.1360 | 381.43% |
| 2020 | -0.0283 | -95.94% |
| 2019 | -0.6962 | -26.16% |
| 2018 | -0.9429 | |
| 2016 | -5.52 | 109.88% |
| 2015 | -2.63 | -56.79% |
| 2014 | -6.09 | -29.82% |
| 2013 | -8.68 | -56.73% |
| 2012 | -20.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Align Technology
ALGN | 76.0 | -7,185.94% | 🇺🇸 USA |
 Dentsply Sirona
XRAY | -7.39 | 588.88% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.